Politics

Tracking how politics and policy intersect with science and health care

Rep. Diana DeGette
Politics

Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before

By Nicholas Florko

Dr. Peter Bach
Politics

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

By Nicholas Florko

Amy Abernethy STAT Summit
Politics

As FDA toils over how to regulate CBD, frustration builds on all sides

By Nicholas Florko

FDA Nominee Stephen Hahn
Politics

Stephen Hahn, Trump’s FDA nominee, pledges ‘bold action’ on vaping but sidesteps questions on flavor ban

By Lev Facher

Stephen Hahn horizontal headshot
Politics

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA 

By Nicholas Florko

Hugh Hewitt
Politics

Mystery solved: The American Hospital Association and CVS Health formed a shadowy, anti-pharma group with deep GOP ties

By Lev Facher

Bernie Sanders, Sen. Elizabeth Warren
Politics

Warren and Sanders: More scrutiny needed of commercial boards that decide whether to green-light clinical trials

By Rebecca Robbins

D.C. Insight IMAGE
Politics

Biotech venture capitalists form a lobbying coalition to join the drug pricing debate 

By Nicholas Florko

Paul Tonko
Politics

A new bill would let more doctors prescribe addiction treatments without waiting for insurers’ permission

By Lev Facher

Nancy Pelosi
Politics

In a rare political move, prominent biotech venture capitalists speak out against Pelosi’s drug pricing bill

By Nicholas Florko

Charlie Baker
Politics

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Post society molecule landscape
Biotech

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

By Nicholas Florko

Democratic Presidential Candidates Participate In First Debate Of 2020
Politics

More than ever, Democratic presidential hopefuls want to take on pharma. Here’s how they’d do it

By Lev Facher

Grogan
Politics

Top Trump official suggests tobacco regulation distracts from FDA mission

By Lev Facher

Prescription conveyor belt
Pharmalot

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

By Ed Silverman

CDC headquarters
Pharmalot

What money? The CDC is urged to acknowledge industry funding

By Ed Silverman

Sen. Bill Cassidy Milken
Politics

Sen. Cassidy on Trump drug plan: Price index still preferable to imports

By Lev Facher

Stephen Hahn horizontal headshot
Politics

Trump nominates MD Anderson’s Stephen Hahn to lead FDA

By Lev Facher

Milken Institute 2019 panel
Politics

Insurance, pharma figures spar over drug price legislation’s innovation impact

By Lev Facher

Elizabeth Warren
Health Tech

Democrats ‘continue to have concerns’ about FDA program to streamline regulation of medical software

By Rebecca Robbins

Darren Soto
Politics

Democrats’ new logic on drug pricing: Developing slightly fewer medicines is OK if it means lower prices

By Lev Facher

Pelosi - October 2019
Politics

Nonpartisan congressional report suggests Pelosi’s drug pricing bill could be found unconstitutional

By Nicholas Florko

Joe Grogan
Politics

How Joe Grogan shaped 5 key drug pricing policy proposals

By Lev Facher

John Butler - Akebia Therapeutics
Biotech

This small biotech is suing the Trump administration to get its drug covered

By Nicholas Florko

GOP amendments to drug pricing bill
Politics

After 10 hours and a pile of rejected amendments, Democrats advance their drug pricing bill out of two key committees

By Nicholas Florko

Rep. Elijah Cummings 2019
Politics

Pelosi: Democrats will name marquee drug pricing bill for late Rep. Cummings

By Lev Facher

Nancy Pelosi & Lloyd Doggett
Politics

House progressives plot overhaul of Pelosi drug pricing bill

By Lev Facher and Nicholas Florko

Pharmalot

A small biotech raises the price on its cancer drug by 20% this year, but will anyone notice?

By Ed Silverman

Frances Arnold
Politics

With a new lobbying group and a day at the White House, synthetic biology looks for footing in Washington

By Nicholas Florko and Rebecca Robbins

Your daily dose of news in health and medicine

Privacy Policy